CBIO Stock Forecast & Price Target

Crescent Biopharma is attractive because CR-001 is built to emulate ivonescimab’s PD-1/VEGF mechanism, and the class has now shown meaningful superiority over pembrolizumab with 70.2% vs. 42.0% ORR, a 0.35 PFS HR, and 30.8 vs. 22.6 months median OS in HARMONi-2. Its near-term value is further supported by ASCEND having completed dose escalation, enrolled more than 125 patients, and opened chemo-combo cohorts ahead of a 1Q27 readout, while the broader program could extend through more than 2,000 dosed patients by mid-2027. Beyond CR-001, the company owns full or broad rights to CR-002 and CR-003, with 2027 data catalysts that could validate a differentiated ADC platform and support a compelling risk-reward at about $200M EV.

Crescent Biopharma is challenged by a highly uncertain clinical profile, because CR-001 is still an unproven attempt to replicate ivonescimab-like biology while also facing competitive pressure from established and emerging PD-1/VEGF and ADC regimens. The company’s other programs, CR-002 and CR-003, remain early and face meaningful safety and dosing risks, including possible payload-release limitations, normal-tissue toxicity, and overlapping adverse events that could restrict combination use and repeat dosing. Fundamentally, the bearish view is reinforced by heavy development risk, potential inability to reproduce early China data globally, and medium-term dilution risk, even though its DCF framework still embeds 11% discount rate assumptions, 30%/20% approval probabilities for CR-001, and 20% for each ADC program.